Pay in 4 interest-free payments of $5.97 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Food and Drug Administration (FDA) approved Eli Lilly and Companys (NYSE: LLY) Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors
Recognising and addressing erectile dysfunction is important not only for quality of life but also as an early warning sign of cardiovascular disease, prompting comprehensive health assessment and management
Mielgo-Ayuso J, et al
A Phase 2 trial published in JCEM demonstrated sustained GH elevation (mean 60% increase) and IGF-1 increases of 4090% maintained across 12 months of daily dosing
US$ 23.03
US$ 21.02
US$ 25.55
US$ 22.48
US$ 26.41
US$ 20.29
US$ 23.24
